The aim of the study was to analyse the effect of the early coadministration of Ivabradine ( Corlentor / Procoralan ) and beta-blockers ( intervention group ) versus beta-blockers alone ( control group ) in patients hospitalised with heart failure and reduced left ventricular ejection fraction ( HFrEF ).
A comparative, randomised study was performed to compare the treatment strategies of beta-blockers alone versus Ivabradine and beta-blockers starting 24 hours after hospital admission, for acute heart failure in patients with an left ventricular ejection fraction ( EF ) less than 40%, sinus rhythm, and a heart rate ( HR ) more than 70 bpm.
A total of 71 patients were examined, 33 in the intervention group and 38 in the control group. No differences were observed with respect to their baseline characteristics or standard treatment at discharge.
Heart rate at 28 days ( 64.3±7.5 vs 70.3±9.3 bpm, p=0.01 ) and at 4months ( 60.6±7.5 vs 67.8±8 bpm, p=0.004 ) after discharge were significantly lower in the intervention group.
Significant differences were found with respect to the ejection fraction and brain natriuretic peptide levels at 4months.
No differences in clinical events ( rehospitalisation / death ) were reported at 4 months.
No severe side effects attributable to the early administration of Ivabradine were observed.
In conclusion, the early coadministration of Ivabradine and beta-blockers during hospital admission for acute HFrEF is feasible and safe, and it produces a significant decrease in heart rate at 28 days and at 4 months after hospital discharge.
It also seemed to improve systolic function and functional and clinical parameters of patients with heart failure at short-term. ( Xagena )
Hidalgo FJ et al, Int J Cardiol 2016; 217: 7-11